Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor

Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor

Show other versions (1)

Background: Recently, modification of T cells with CAR has been an attractive approach for adoptive immunotherapy of cancers. Typically, CARs contain a scFv. Most often, scfvs are derived from a monoclonal antibody of murine origin and may be a trigger for host immune system that leads to the T-cell...

Full description

Bibliographic Details
Main Authors: Mahmoud Hassani, Fatemeh Hajari Taheri, Zahra Sharifzadeh, Arash Arashkia, Jamshid Hadjati, Wytske M. van Weerden, Shahriyar Abdoli, Mohammad Hossein Modarressi, Mohsen Abolhassani
Format: Article
Language:English
Published: Pasteur Institute of Iran 2020-03-01
Series:Iranian Biomedical Journal
Subjects:
chimeric antigen receptor
immunotherapy
prostate cancer
Online Access:http://ibj.pasteur.ac.ir/article-1-2922-en.pdf

Similar Items

Similar Items